PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
1-Year Return
21.39%
This Quarter Return
+9.02%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$1.15B
AUM Growth
-$149M
(-11%)
Cap. Flow
-$228M
Cap. Flow
% of AUM
-19.74%
Top 10 Holdings %
Top 10 Hldgs %
54.46%
Holding
82
New
17
Increased
13
Reduced
24
Closed
24
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$20.8M |
| 2 |
Natera
NTRA
|
$17.1M |
| 3 |
Cencora
COR
|
$16M |
| 4 |
Masimo
MASI
|
$15.9M |
| 5 |
Akero Therapeutics
AKRO
|
$14.2M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$61.6M |
| 2 |
AbbVie
ABBV
|
$54M |
| 3 |
Elevance Health
ELV
|
$38.4M |
| 4 |
argenx
ARGX
|
$34M |
| 5 |
Universal Health Services
UHS
|
$29.2M |
Sector Composition
| 1 | Healthcare | 96.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Erasca
ERAS
$457M
| $1.36M | 0.12% |
1,072,224
-2,417,335
| -69% | -$3.07M |
|
52
Structure Therapeutics
GPCR
$1.27B
| $1.17M | 0.1% |
56,594
+16,194
| +40% | +$336K |
|
53
Viking Therapeutics
VKTX
$3.03B
| $1,000K | 0.09% |
+37,729
| New | +$1,000K |
|
54
Sagimet Biosciences
SGMT
$231M
| $686K | 0.06% |
90,000
-559,006
| -86% | -$4.26M |
|
55
Werewolf Therapeutics
HOWL
$61.7M
| $437K | 0.04% |
401,110
-2,105,410
| -84% | -$2.29M |
|
56
SPDR S&P Retail ETF
XRT
$441M
| – | – |
-36,471
| Closed | -$2.52M |
|
57
Arcellx
ACLX
$4.03B
| – | – |
-15,488
| Closed | -$1.02M |
|
58
AstraZeneca
AZN
$253B
| – | – |
-150,200
| Closed | -$11M |
|
59
Becton Dickinson
BDX
$55.1B
| – | – |
-91,571
| Closed | -$21M |
|
60
Biohaven
BHVN
$1.68B
| – | – |
-197,307
| Closed | -$4.74M |
|
61
Capricor Therapeutics
CAPR
$308M
| – | – |
-140,681
| Closed | -$1.34M |
|
62
Celcuity
CELC
$2.36B
| – | – |
-53,349
| Closed | -$539K |
|
63
Centene
CNC
$14.2B
| – | – |
-135,398
| Closed | -$8.22M |
|
|
64
Elevance Health
ELV
$70.6B
| – | – |
-88,222
| Closed | -$38.4M |
|
65
Iovance Biotherapeutics
IOVA
$901M
| – | – |
-132,152
| Closed | -$440K |
|
66
IQVIA
IQV
$31.9B
| – | – |
-111,854
| Closed | -$19.7M |
|
67
Keros Therapeutics
KROS
$633M
| – | – |
-104,323
| Closed | -$1.06M |
|
68
PMV Pharmaceuticals
PMVP
$77.4M
| – | – |
-3,301,942
| Closed | -$3.6M |
|
69
Syndax Pharmaceuticals
SNDX
$1.47B
| – | – |
-926,424
| Closed | -$11.4M |
|
70
Sarepta Therapeutics
SRPT
$1.96B
| – | – |
-50,809
| Closed | -$3.24M |
|
|
SWTX
71
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-26,437
| Closed | -$1.17M |
|
72
Thermo Fisher Scientific
TMO
$186B
| – | – |
-21,897
| Closed | -$10.9M |
|
|
TSBX
73
DELISTED
Turnstone Biologics
TSBX
| – | – |
-932,348
| Closed | -$382K |
|
|
74
Universal Health Services
UHS
$12.1B
| – | – |
-155,520
| Closed | -$29.2M |
|
|
VERV
75
DELISTED
Verve Therapeutics
VERV
| – | – |
-155,495
| Closed | -$711K |
|